Production (Stage)
ADMA Biologics, Inc.
ADMA
$20.42
$0.261.29%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 51.10% | 734.15% | 1,299.42% | 603.25% | 362.28% |
| Total Depreciation and Amortization | -6.86% | -7.82% | -7.27% | -2.43% | 3.98% |
| Total Amortization of Deferred Charges | -24.90% | -68.62% | -65.05% | -66.96% | -48.16% |
| Total Other Non-Cash Items | 276.55% | -369.04% | 14.79% | 9.31% | 2.70% |
| Change in Net Operating Assets | -131.46% | 280.77% | -520.20% | 267.58% | -95.73% |
| Cash from Operations | -787.06% | 185.37% | 108.83% | 853.36% | 84.94% |
| Capital Expenditure | -100.30% | -130.33% | -39.50% | -136.93% | -20.67% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -26.67% | 103.33% | -- | -- | -- |
| Cash from Investing | -99.83% | -95.45% | -45.05% | -171.22% | -21.44% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | 81.08% | -- | -- | -- |
| Issuance of Common Stock | -90.18% | 5,437.50% | 812.02% | -29.87% | -- |
| Repurchase of Common Stock | -191.92% | -88.86% | -456.73% | -206.64% | -286.88% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 94.53% | -- | -- | -- |
| Cash from Financing | -392.54% | 20.44% | -6,221.88% | -250.83% | -122.62% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -423.01% | 172.09% | -113.20% | 741.44% | 65.20% |